Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma. The purpose of this study is to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of Betalutin in combination with rituximab.
Non Hodgkin Lymphoma|Follicular Lymphoma|Relapsed Follicular Lymphoma
DRUG: 10 MBq/kg Betalutin|DRUG: 15 MBq/kg Betalutin
Safety and Tolerability: Frequency and Severity of Adverse Events (CTCAE v4.03), Safety and tolerability of Betalutin in combination with rituximab as determined by the frequency and severity of adverse events (CTCAE v4.03) in the first 12 weeks after Betalutin, 12 weeks
Preliminary Anti-tumour Activity, Best overall response of combination treatment using tumour responses based on CT and PET/CT imaging (classified as as complete response, partial response, no response/stable disease or progressive disease as described in "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification"), 25 months
This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma. The purpose of this study is to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of Betalutin in combination with rituximab.